Aortic regurgitation resident survival guide
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alejandro Lemor, M.D. [2]
Aortic Regurgitation Resident Survival Guide Microchapters |
---|
Overview |
Causes |
FIRE |
Diagnosis |
Treatment |
Do's |
Don'ts |
Overview
Aortic regurgitation (AR) refers to the retrograde or backward flow of blood from the aorta into the left ventricle during diastole. The presentation depends on the response and adaptability of the left ventricle to the increased left ventricular diastolic volume. In chronic AR, the left ventricle has adapted by dilatation of its walls; however, in acute AR a rapid increase in the diastolic volume is not tolerated by a normal-size ventricle which could lead to cardiogenic shock. Acute AR can be caused by aortic dissection and infective endocarditis which require immediate surgical intervention. The most common causes of chronic AR are bicuspid aortic valve and calcific valve disease. The treatment of chronic AR depends on the stage of the disease. Acute AR is a life-threatening condition and must be recognized and treated promptly.
Causes
Life Threatening Causes
Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.
Common Causes
- Bicuspid aortic valve
- Senile or degenerative calcific aortic valve disease[1]
- Dilatation of the aorta due to primary diseases
- Rheumatic fever (developing countries)
Click here for the complete list of causes.
FIRE: Focused Initial Rapid Evaluation
A Focused Initial Rapid Evaluation (FIRE) should be performed to identify patients in need of immediate intervention. The algorithm below is based on the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease.[2][3]
Boxes in red signify that an urgent management is needed.
Abbreviations: ECG: Electrocardiogram; ICU: Intensive care unit; MAP: Mean arterial pressure ; P2: Second heart sound, pulmonary component; S1: First heart sound; S3: Third heart sound; TTE: Transthoracic echocardiography; TEE: Transesophageal echocardiography
Identify cardinal findings that increase the pretest probability of aortic regurgitation Acute aortic regurgitation ❑ Low pitched early diastolic murmur
❑ Decreased or absent S1
❑ Presence of S3 ❑ Corrigan's pulse: a rapid upstroke and collapse of the carotid artery pulse | |||||||||||||||||||||||||||||||||
Does the patient have any findings of cardiogenic shock that require urgent management? ❑ Tachycardia ❑ Hypotension ❑ Altered mental status ❑ Tachypnea ❑ Oliguria ❑ Cold extremities | |||||||||||||||||||||||||||||||||
YES | NO | ||||||||||||||||||||||||||||||||
Proceed to the complete diagnostic approach below | |||||||||||||||||||||||||||||||||
Initiate resuscitation measures: ❑ Secure airway ❑ Administer oxygen ❑ Secure wide bore IV access ❑ Perform ECG monitor ❑ Monitor vitals continuously ❑ Admit to ICU Initiate medical therapy to treat cardiogenic shock: ❑ Administer nitroprusside 0.3-0.5 υg/kg/min IV (max 10 υg/kg/min), AND ❑ Administer dobutamine 0.5 υg/kg/min IV (max 20 υg/kg/min) ❑ Titrate to maintain MAP > 60 mmHg ❑ Administer beta blockers in high suspicion of aortic dissection Do not use beta blockers for other causes as they will block the compensatory tachycardia Order urgent TTE:
Do not perform percutaneous aortic balloon counterpulsation (it will increase the diastolic pressure and the regurgitant volume) | |||||||||||||||||||||||||||||||||
Click here for cardiogenic shock resident survival guide | |||||||||||||||||||||||||||||||||
What is the etiology of aortic regurgitation based on clinical findings and echocardiography? | |||||||||||||||||||||||||||||||||
Diagnostic clues: ❑ Chest pain of the following characteristics:
❑ Unexplained syncope
❑ Aortic root dissection found on TTE | Diagnostic clues: ❑ Persistent fever ❑ New valvular regurgitation murmur ❑ Previous blood culture positive ❑ Vegetations found on TTE ❑ High risk factors:
❑ Evaluate the modified Duke criteria (click here to see) | Symptomatic severe chronic AR Diagnostic clues: ❑ No TTE findings of aortic dissection or leaflet vegetations ❑ Previous history of aortic valve disease ❑ High pitched holodiastolic decrescendo murmur
❑ S3 ❑ Corrigan's pulse: a rapid upstroke and collapse of the carotid artery pulse | |||||||||||||||||||||||||||||||
❑ Immediate surgical intervention | ❑ Immediate surgical intervention | ||||||||||||||||||||||||||||||||
Proceed to the complete diagnostic approach below | |||||||||||||||||||||||||||||||||
Complete Diagnostic Approach
A complete diagnostic approach should be carried out after a focused initial rapid evaluation is conducted and following initiation of any urgent intervention.[2][3]
Abbreviations: AVR: Aortic valve replacement; BP: Blood pressure; CBC: Complete blood count; CXR: Chest X-ray; ECG: Electrocardiogram; ESR: Erythrocyte sedimentation rate; HF: Heart failure; LV: Left ventricle; LVEF: Left ventricle ejection fraction; MI: Myocardial infarction; S1: First heart sound; S2: Second heart sound; S3: Third heart sound; S4: Fourth heart sound; TTE: Transthoracic echocardiography; TEE: Transesophageal echocardiography; TAVR: Transcatheter aortic valve replacement
Acute Aortic Regurgitation
Shown below is a complete diagnostic approach for acute aortic regurgitation based on the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease.[2]
Characterize the symptoms: ❑ Sudden and severe dyspnea
❑ Unexplained syncope ❑ Fever ❑ Sweats ❑ Fatigue ❑ Pleuritic chest pain ❑ Back pain ❑ Weakness ❑ Myalgias | |||||||||||||||||||||||||||||||||||||||||||
Inquire about past medical history: Suggestive of infective endocarditis ❑ Bicuspid aortic valve
Suggestive of aortic dissection ❑ Hypertension ❑ Marfan syndrome ❑ Connective tissue disorder | |||||||||||||||||||||||||||||||||||||||||||
Examine the patient: Vitals
Cardiovascular examination
❑ Apical diastolic rumble
| |||||||||||||||||||||||||||||||||||||||||||
Order labs and tests: ❑ TTE (most important test) (Class I; Level of Evidence: B)
❑ CMR in cases of moderate or severe AR and suboptimal echocardiographic images for the evaluation of the severity of AR (Class I; Level of Evidence: B)
❑ ECG
❑ Blood culture (if suspected infective endocarditis) | |||||||||||||||||||||||||||||||||||||||||||
Determine the etiology of the acute aortic regurgitation | |||||||||||||||||||||||||||||||||||||||||||
Diagnostic clues: ❑ Chest pain of the following characteristics:
❑ Syncope
❑ Previous history of: | Diagnostic clues: ❑ Persistent fever ❑ New valvular regurgitation murmur ❑ Positive blood culture ❑ Vegetations found on TTE ❑ High risk factors:
Click here for infective endocarditis resident survival guide | Other causes | |||||||||||||||||||||||||||||||||||||||||
Chronic Aortic Regurgitation
Shown below is a complete diagnostic approach for chronic aortic regurgitation based on the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease.[2]
Characterize the symptoms: ❑ Asymptomatic ❑ Dyspnea on exertion ❑ Orthopnea ❑ Paroxysmal nocturnal dyspnea ❑ Palpitations ❑ Chest pain ❑ Shortness of breath ❑ Cough ❑ Altered mental status ❑ Syncope ❑ Fatigue | |||||||||||||||||||||||||||||||||||||||||||||
Inquire about past medical history: ❑ Cardiac disease: ❑ Rheumatic fever ❑ Pulmonary disease ❑ Trauma ❑ Syphilis ❑ Ankylosing spondylitis ❑ Acromegaly ❑ Marfan syndrome ❑ Ehlers-Danlos syndrome ❑ Giant cell arteritis ❑ Takayasu's arteritis ❑ Previous cardiac surgery | |||||||||||||||||||||||||||||||||||||||||||||
Examine the patient: Vitals
Cardiovascular examination
❑ Search for other characteristic signs suggestive of aortic regurgitation
Respiratory examination | |||||||||||||||||||||||||||||||||||||||||||||
Order imaging studies: ❑ TTE (most important evaluation test) (Class I; Level of Evidence: B)
❑ ECG
| |||||||||||||||||||||||||||||||||||||||||||||
Classify aortic regurgitation based on the following findings on TTE: ❑ Vena contracta ❑ Jet/LVOT ❑ Regurgitant volume ❑ Regurgitant fraction ❑ Effective regurgitant orifice | |||||||||||||||||||||||||||||||||||||||||||||
Risk of aortic regurgitation (Stage A) ❑ No regurgitation | Mild (Stage B) ❑ Vena contracta <0.3 cm ❑ Jet/LVOT <25% ❑ Regurgitant volume <30 mL/beat ❑ Regurgitant fraction <30% ❑ Effective regurgitant orifice <0.10 cm² | Moderate (Stage B) ❑ Vena contracta 0.3-0.6 cm ❑ Jet/LVOT 25-64% ❑ Regurgitant volume 30-59 mL/beat ❑ Regurgitant fraction 30-49% ❑ Effective regurgitant orifice 0.10-0.29 cm² | Severe ❑ Vena contracta >0.6 cm ❑ Jet/LVOT ≥ 65% ❑ Regurgitant volume ≥60 mL/beat ❑ Regurgitant fraction ≥50% ❑ Effective regurgitant orifice ≥ 0.30 cm² ❑ Holodiastolic flow reversal in the proximal abdominal aorta | ||||||||||||||||||||||||||||||||||||||||||
Asymptomatic | Symptomatic (Stage D) | ||||||||||||||||||||||||||||||||||||||||||||
Treatment
Abbreviations: AVR: Aortic valve replacement; ACE: Angiotensin converting enzyme; ARB: Angiotensin receptor blocker; CCB: Calcium channel blocker; LVEF: Left ventricle ejection fraction; TTE: Transthoracic echocardiography
Treatment of Acute Aortic Regurgitation
Shown below is an algorithm for the treatment of acute aortic regurgitation according to the 2014 AHA/ACC Guidelines for the Management of Valvular Heart Disease[2][5] and the 2010 ACCF/AHA Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic Disease[6]
Determine the etiology and the grade of regurgitation | |||||||||||||||||||||||||||||||||||
Mild to moderate regurgitation | Severe regurgitation | Mild to moderate regurgitation | Severe regurgitation | ||||||||||||||||||||||||||||||||
Does the patient has any of the following? ❑ S.aureus infection ❑ Fungal infection ❑ Large vegetation | Replacement of supra-coronary ascending aorta | Aortic root replacement, OR Valve-sparing aortic root replacement | |||||||||||||||||||||||||||||||||
No | Yes | ||||||||||||||||||||||||||||||||||
❑ Initiate antibiotic treatment
| ❑ Schedule for AVR (Class I; Level of Evidence: B) | ||||||||||||||||||||||||||||||||||
If the patient does not get better after 5-7 days: ❑ Schedule for AVR (Class I; Level of Evidence: B) | |||||||||||||||||||||||||||||||||||
Treatment of Chronic Aortic Regurgitation
Shown below is an algorithm summarizing the treatment approach to chronic aortic regurgitation according to the 2014 AHA/ACC Guidelines on the Management of Valvular Heart Disease.[2][3]
What is the stage of aortic regurgitation according to the TTE? | |||||||||||||||||||||||||||||||||||||||||||||
No regurgitation (Stage A) | Progressive regurgitation (Stage B) Mild ❑ Vena contracta <0.3 cm ❑ Jet/LVOT <25% ❑ Regurgitant volume <30 mL/beat ❑ Regurgitant fraction <30% ❑ Effective regurgitant orifice <0.10 cm² Moderate ❑ Vena contracta 0.3-0.6 cm ❑ Jet/LVOT 25-64% ❑ Regurgitant volume 30-59 mL/beat ❑ Regurgitant fraction 30-49% ❑ Effective regurgitant orifice 0.10-0.29 cm² | Severe regurgitation ❑ Vena contracta >0.6 cm ❑ Jet/LVOT ≥ 65% ❑ Regurgitant volume ≥60 mL/beat ❑ Regurgitant fraction ≥50% ❑ Effective regurgitant orifice ≥ 0.30 cm² ❑ Holodiastolic flow reversal in the proximal abdominal aorta | |||||||||||||||||||||||||||||||||||||||||||
Is the patient symptomatic? | |||||||||||||||||||||||||||||||||||||||||||||
Asymptomatic patients ❑ Control hypertension preferably with
| NO (Stage C) | YES (Stage D) | |||||||||||||||||||||||||||||||||||||||||||
❑ No treatment is needed | ❑ Perform a periodic echocardiogram (Class I; Level of Evidence:B)
| ||||||||||||||||||||||||||||||||||||||||||||
❑ Perform a periodic echocardiogram every 6 - 12 months (Class I; Level of Evidence: B) ❑ Perform an exercise stress test | Does the patient has any contraindications for surgery? | ||||||||||||||||||||||||||||||||||||||||||||
Did the patient developed symptoms in the stress test? | YES | NO | |||||||||||||||||||||||||||||||||||||||||||
YES | NO | ❑ Schedule for AVR (Class I; Level of Evidence: B) | |||||||||||||||||||||||||||||||||||||||||||
Initiate medical therapy with vasodilators ❑ Nifedipine 30-60 mg/day, OR ❑ Hydralazine 10-25 mg/ q8hrs | ❑ No treatment is needed | ||||||||||||||||||||||||||||||||||||||||||||
If the patient undergoes another cardiac surgery: ❑ Schedule for AVR (Class IIa; Level of Evidence: C) | |||||||||||||||||||||||||||||||||||||||||||||
Type of Valve and Discharge Anticoagulation Therapy
Abbreviations: AVR: Aortic valve replacement; INR: International normalized ratio; TAVR Tansthoracic aortic valve replacement
Determine: ❑ Age ❑ Contraindications for anticoagulation
| |||||||||||||||||||||||||||||||||
❑ Patients ≤ 60 years old AND ❑ No contraindication for anticoagulation (Class IIa; Level of Evidence: B) | ❑ Patients 60 - 70 years old AND ❑ No contraindication for anticoagulation | ❑ Patients ≥ 70 years old (Class IIa; Level of Evidence: B) OR ❑ Patients at any age AND contraindications for anticoagulation therapy (Class I; Level of Evidence: C) | |||||||||||||||||||||||||||||||
Mechanical prosthesis Avoid the use of direct thrombin inhibitors or anti-Xa agents in patients with mechanical prosthesis (Class III; Level of Evidence: B) | Bioprosthesic OR Mechanical prosthesis (Class IIa; Level of Evidence: B) | Bioprosthesis | |||||||||||||||||||||||||||||||
Does the patient have risk factors for thromboembolism†? | Surgical AVR OR TAVR | ||||||||||||||||||||||||||||||||
Yes | No | Surgical AVR | |||||||||||||||||||||||||||||||
Administer for long term: ❑ Warfarin to achieve INR of 3.0 (Class I; Level of Evidence: B) AND ❑ Aspirin 75-100 mg/d (Class I; Level of Evidence: A) | Administer for long term: ❑ Warfarin to achieve INR of 2.5 (Class I; Level of Evidence: B) AND ❑ Aspirin 75-100 mg/d (Class I; Level of Evidence: A) | Administer ❑ Warfarin to achieve INR of 2.5 for 3 months (Class IIb; Level of Evidence: B) AND ❑ Aspirin 75-100 mg/d long term (Class IIa; Level of Evidence: B) | Administer:
| ||||||||||||||||||||||||||||||
Do's
- Perform a cardiac MRI in patients with moderate or severe AR with an inconclusive TTE to assess the left ventricular systolic function and the systolic and diastolic volumes, as well as to evaluate the severity of AR (Class I; Level of Evidence: B).
- Perform exercise stress test to assess symptomatic status and functional capacity of patients with severe aortic regurgitation.
- It is reasonable to perform AVR in patients with moderate AR that will undergo CABG, surgery on the ascending aorta, or mitral valve surgery (Class IIa; Level of Evidence: C).
- Perform a transthoracic echocardiography (TTE) after aortic valve replacement to evaluate the valve hemodynamics (Class I; Level of Evidence: B).[2]
- Perform a TTE when clinical symptoms or signs suggest prosthetic valve dysfunction (Class I; Level of Evidence: C).[2]
- Perform a colonoscopy in patients with infective endocarditis with blood cultures positive for S. bovis.[7]
Don'ts
- Do not use beta blockers in aortic regurgitation that is not caused by aortic dissection as it will block the compensatory tachycardia.
- Do not use intra-aortic balloon counterpulsation in severe acute aortic regurgitation as it will increase the aortic diastolic pressure and the regurgitant volume.
- Do not give antibiotics to patients with known aortic regurgitation before blood cultures are obtained for unexplained fever (Class III; Level of Evidence: C).
- Do not give ACE inhibitors to pregnant patients with aortic regurgitation (Class III; Level of Evidence: B).
References
- ↑ Nishimura, RA. (2002). "Cardiology patient pages. Aortic valve disease". Circulation. 106 (7): 770–2. PMID 12176943. Unknown parameter
|month=
ignored (help) - ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 Nishimura, R. A.; Otto, C. M.; Bonow, R. O.; Carabello, B. A.; Erwin, J. P.; Guyton, R. A.; O'Gara, P. T.; Ruiz, C. E.; Skubas, N. J.; Sorajja, P.; Sundt, T. M.; Thomas, J. D. (2014). "2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines". Circulation. doi:10.1161/CIR.0000000000000031. ISSN 0009-7322.
- ↑ 3.0 3.1 3.2 Bonow, R. O.; Carabello, B. A.; Chatterjee, K.; de Leon, A. C.; Faxon, D. P.; Freed, M. D.; Gaasch, W. H.; Lytle, B. W.; Nishimura, R. A.; O'Gara, P. T.; O'Rourke, R. A.; Otto, C. M.; Shah, P. M.; Shanewise, J. S. (2008). "2008 Focused Update Incorporated Into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons". Circulation. 118 (15): e523–e661. doi:10.1161/CIRCULATIONAHA.108.190748. ISSN 0009-7322.
- ↑ Williams BR, Steinberg JP (2006). "Images in clinical medicine. Müller's sign". The New England Journal of Medicine. 355 (3): e3. doi:10.1056/NEJMicm050642. PMID 16855259. Retrieved 2012-04-15. Unknown parameter
|month=
ignored (help) - ↑ Hamirani, Y. S.; Dietl, C. A.; Voyles, W.; Peralta, M.; Begay, D.; Raizada, V. (2012). "Acute Aortic Regurgitation". Circulation. 126 (9): 1121–1126. doi:10.1161/CIRCULATIONAHA.112.113993. ISSN 0009-7322.
- ↑ Hiratzka, L. F.; Bakris, G. L.; Beckman, J. A.; Bersin, R. M.; Carr, V. F.; Casey, D. E.; Eagle, K. A.; Hermann, L. K.; Isselbacher, E. M.; Kazerooni, E. A.; Kouchoukos, N. T.; Lytle, B. W.; Milewicz, D. M.; Reich, D. L.; Sen, S.; Shinn, J. A.; Svensson, L. G.; Williams, D. M. (2010). "2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine". Circulation. 121 (13): e266–e369. doi:10.1161/CIR.0b013e3181d4739e. ISSN 0009-7322.
- ↑ Boleij, A.; Schaeps, R. M. J.; Tjalsma, H. (2009). "Association between Streptococcus bovis and Colon Cancer". Journal of Clinical Microbiology. 47 (2): 516–516. doi:10.1128/JCM.01755-08. ISSN 0095-1137.